CD26 and CD40 ligand (CD40L) are surface molecules on human activated T lymphocytes that play a critical role in the regulation of lymphopoiesis. Both molecules are expressed on a restricted fraction of human T-cell non-Hodgkin's lymphomas (NHL)/leukemias; however, little is known about their functional and/or clinical significance in these disorders. In this study, the pattern of expression of CD4OL was compared with that of the CD26 molecule. A series of 67 human T-cell NHL/leukemias and a panel of leukemia/ lymphoma T-cell lines were evaluated by immunohistochemistry, flow cytometry, and RNA studies. The overall frequency of CD26+ and CD40L' samples was rather similar (25/67 [37%] W 18/67 [27%1). However, the majority of CD26-expressing cases clustered in the lymphoblastic lymphomas (LBL)/T-acute lymphoblastic leukemias (ALL; 12/23) and CD30+ anaplastic large-cell (ALC) lymphomas (5/8), whereas CD4OL' lymphomas included a large fraction of mycosis fungoides (11/21 [52%]). CD26 and CD40L coexpression was found only in 2 mycosis fungoides cases and 1 small lymphocytic lymphoma. Thus, the expression of the two antigens was mutually exclusive in almost all T-cell lymphomas/leu--CELL NON-HODGKIN'S lymphomas (NHL) represent a heterogeneous group of neoplasms encompassing a wide spectrum of morphologic histotypes' that may, in turn, correspond to distinct clinicopathologic entities.' Among the latter, cutaneous T-cell lymphomas and, more recently, T-cell CD30+ anaplastic large-cell (ALC) lymphomas have been extensively chara~terized.~.~ T-cell NHL also exhibit a considerable phenotypic heterogeneity, corresponding overall to proliferations derived from T-cell progenitors at prethymic, intrathymic, or postthymic stages of T-cell differentiation. ' The expression of a surface molecule corresponding to CD40 ligand (CD40L) and designated T-cell-B-cell-activating molecule"' has recently been detected on a number of T-cell NHL with a relative mature phenotype (CD4+/ CD8-)." CD4OL is an activation antigen of T cells acting as a specific ligand for CD40 molecule on B cells'' and showing homology to ligands for other receptors of the tumor necrosis factorherve growth factor (TNF/NGF) superfamily." CD4OL is transiently and predominantly expressed by activated CD4+ T lymphocytes and by a small proportion of CD8' T cell^.^^"^ Engagement of CD40 by CD4OL triggers a number of biologic events in B lymphocytes, including proliferation, Ig secretion and switching, cytokine production, and inhibition of the programmed cell death in germinal center B cells."
Evidence has been provided showing that CD26, which was initially characterized as an activation antigen of T ce1ls,l6 is detectable in neoplastic cells of T-cell CD30+ ALC lymphomas and in a restricted fraction of other T-cell NHL.I7 CD26 corresponds to the surface enzyme dypeptidyl peptidase IVI8 and is physically associated to the CD45RO molecule on the T-cell surface." This molecule is also functionally active as a binding structure for extracellular matrix components16 and as a coreceptor for the human immunodeficiency virus.'o More recently, it has been shown that CD26 kemias. Accordingly, lymphoma cell lines expressed either one of the molecules or the relative amounts of CD26 and CD40L were inversely proportional. In contrast, reactive T lymphocytes from patients with non-neoplastic T-cell expansions and in vitro activated CD3' or CD4+ normal T cells were found t o coexpress CD40L and CD26. Results of a multivariate analysis showed that the expression of CD26 in Tcell LBL/ALL patients was associated t o a worse outcome in terms of survival, as compared with patients with CD26-tumors ( P I .0001). Based on our results, it can be concluded that, (1) as opposed t o activated or reactive normal T cells, the expression of CD26 and of CD40L is mutually exclusive in human T-cell lymphomas/leukemias; (21 expression of CD26 is restricted t o aggressive pathologic entities, such as T-cell LBL/ALL and T-cell CD30' ALC lymphomas, whereas CD40L is expressed on slow progressing diseases such as mycosis fungoides; and (3) within the T-cell LBL/ALL group of tumors, CD26 may identify a subset of poor prognosis patients.
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is identical to the adenosine deaminase (ADA) binding protein,"." a cell surface transporter for ADA," an enzyme critically involved in the proliferation and functional activation of T lymphocytes. CD26 belongs to a group of at least four membrane-associated enzymes with common structural and regulatory features, including also CDlOheutral endopeptidase 24.1 1, CD13/aminopeptidase N, and BP-l/6C3/ aminopeptidase A." In humans, CD26 is primarily expressed by CD3+ medullary thymocytesz3 and is also detectable on different functional subsets of resting and activated human peripheral T cells.24,25 The role of this molecule in the regulation of lymphopoiesis has recently been emphasized. 18 Whereas the expression of CD40L and CD26 has been previously detected on a restricted fraction of human T-cell lymphomas,1'.17.'6 thus providing indirect evidence suggesting that both these molecules may play a role in the regulation of tumor cell growth, their functional significance and potential clinical relevance in T-cell NHL remain to be defined.
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The present study was aimed at further characterizing the patterns of expression of CD40L and CD26 in human T-cell malignancies, in vitro activated normal CD3+ or CD4' T lymphocytes, and non-neoplastic (reactive) T-cell expansions from a number of clinical conditions. Finally, the expression of both these molecules was correlated with the clinical outcome of patients with lymphoblastic T-cell malignancies and cutaneous T-cell lymphomas.
MATERIALS AND METHODS
Samples
The study included tissue samples of 45 cases of T-cell NHL. Tissues were fixed in Bouin solution or neutral buffered formalin. In all cases, a portion of unfixed tissue was snap frozen in liquid nitrogen and stored at -80°C. Cryopreserved cell samples from 5 T-cell lymphoblastic lymphomas, 8 T-cell acute lymphoblastic leukemias (T-ALL), 1 T-cell chronic lymphocytic leukemia, and 8 mycosis fungoides were also used for immunostaining procedures.
The diagnosis of T-cell NHUleukemia was based on correlative analysis of the morphologic, immunophenotypic, and, when necessary, genotypic characteristics. The cases were categorized as previously reported by Inghirami et al." They were also classified according to the Working Formulation (WF) for NHL. The diagnosis of CD30+ ALC lymphoma was based on correlative analysis of the histopathologic and immunophenotypic characteristic^.^.'^ The mycosis fungoides cases showed a dermal infiltrate with epidermotropism and either well-developed Pautrier's microabscesses or smaller focal intraepidermal collections of atypical mononuclear cells.
Frozen tissue from 15 clinical samples with non-neoplastic T-cell proliferations (9 reactive lymph nodes without obvious cause and with a high degree of paracortical expansion, 4 lymph nodes with dermatopathic lymphadenopathy, and 2 reactive lymph nodes in infectious mononucleosis with paracortical hyperplasia) and cryopreserved peripheral blood cell samples from patients with rheumatoid arthritis (4 cases), sarcoidosis (2 cases), polyarteritis nodosa (2 cases), scleroderma (2 cases), and postviral fatigue syndrome (4 cases) were also included in the study.
Immunohistochemistry
Deparaffinized and cryostat sections were used for immunophenotyping and lineage assignment of lymphoma cases with monoclonal antibodies (MoAbs; PFl, CD3, CD4, CD5, CD8, CD9, CDIO, CD15, CD19, CD20, CD21, CD22, CD24, CD30, CD43, CD45, CD45RA, CD45R0, CD68, CD74, CDw75, LN3, MB2, DDBB42, DBA44, OPD4, DRC-I, Leu8 On frozen sections, lymphoma cases were interpreted as positive for CD26 and CD40L when a high percentage of tumor cells (>758) were labeled. On the other hand, because T-cell neoplasms are almost always infiltrated by a background population of small, nonneoplastic T cells, an arbitrary threshold of 50% positive cells was considered still acceptable in a negative tumor." Furthermore, in mycosis fungoides lesions, CD26 and CD40L staining was assessed on the cytologically abnormal lymphoid cells in the epidermis, thus minimizing the potential interference from dermal reactive lymphocytes. '2 Cell Lines, PuriJcation of Peripheral CD3' and CD4+ T Cells, and In Vitro Activation
The human cutaneous lymphoma T-cell lines HUT 78 (Sezary syndrome), HUT 102 (mycosis fungoides), and H9; the Molt-4 Tcell line; the CD30' ALC lymphoma T-cell line Karpas 299; K562 cells; the T-cell lymphoblastic lymphoma cell lines HSB, KE-37, FRO, and CEM; and a CD4dim Jurkat T-cell clone obtained in our laboratory33 were cultured in RPM1 medium supplemented with 10% fetal calf serum. Sources and phenotypic characteristics of the human leukemia/lymphoma T-cell lines used in the present study have been described in detail elsewhere.34 Peripheral CD3'T cells were isolated from normal donors or patients with non-neoplastic expansion of activated T cells by Ficoll-Hypaque centrifugation and direct or indirect negative selection with anti-CD19, anti-CD14, and anti-CD16 immunomagnetic beads (Dynabeads; Dynal, Oslo, Norway), as previously described."," CD4+ T cells were further purified by anti-CD8 immunodepletion. More than 96% pure CD3' or CD4+ normal T cells were activated in vitro by exposure to 12-0-tetradecanoylphorbol-13-acetate (TPA; 10 ng/mL) and ionomycin (1 pglmL), as described"-": collected at different time points up to 78 hours; and analyzed for surface CD26 and CD40L expression using flow cytometry. Human lymphoma T-cell lines were activated in vitro by exposure to TPA (1 X mol&) or TPA plus ionomycin, as previously d e~c r i b e d .~~
Flow Cytometry
Indirect immunofluorescence of cell lines, lymphoma samples, and peripheral lymphocytes was performed as previously described.* As a second-step reagent, fluorescein isothiocyanate (FITC)-conjugated F(ab'), fragments of goat anti-mouse Ig (H+L) (Technogenetics, Milan, Italy) were employed. For dual-color immunofluorescence, cells were first incubated with the anti-CD40L MoAb M90 followed by FITC-conjugated F(ab'), goat antimouse Ig and subsequently with a phycoerythrinated anti-CD26 MoAb BA5 (Immunotech, Marseille, France). Nonspecific binding of MoAbs was assessed by labeling cells with isotype-matched control mouse Igs (Becton Dickinson, Mountain View, CA). Viable, antibody-labeled cells were identified according to their forward and right angle scattering, electronically gated, and analyzed for surface fluorescence on a FACScan flow cytometer (Becton Dickinson) using Lysis I1 analysis software (Becton Dickinson). The percentage of cells expressing a given antigen was evaluated by setting appropriate markers on isotype controls-generated fluorescence histograms. Analyzed cells were considered to be positively stained by each MoAb if exhibiting a fluorescence intensity greater than 95% of cells stained with negative control antibodies?6 For dual-color fluorescence experiments, quadrant markers were set, after electronic compensation, to account for the highest levels of nonspecific fluorescence displayed by cells sequentially labeled with isotype-matched control Igs, FITC-conjugated F(ab')* goat antimouse Igs (green fluorescence), and phycoerythrin (PE)-conjugated isotype-matched control Igs (red fluorescence).
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CD26 AND CD40L IN T-CELL LYMPHOMASILEUKEMIAS 4619
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total cellular RNA was extracted by the guanidium thiocyanatephenol-chlorophorm method, as previously de~cribed.~' For hot-start RT-PCR,38 RNA samples (1 pg) were reversed-transcribed using avian myeloblastosis virus (AMV) reverse transcriptase (Promega CO, Madison, WI) in a 20 pL reaction mix containing hexadeoxyribonucleotides random primers (0.5 pg) for 1.0 hours at 42°C. Five microliters of the same cDNA bulks, in a 50 pL volume of final reaction mix containing a wax bead (Ampliwax; Perkin Elmer Cetus, Norwalk, CT), was amplified using a Perkin Elmer thermal cycler (model 9600) with primers pairs specific for CD26 (5 minutes at 9 4 T , followed by 35 cycles of 30 seconds at 9 4 T , 30 seconds at 4 8 T , 60 seconds at 7 2 T , and a final extension of 5 minutes at 72"C), CD40L (4 minutes at 9 4 T , followed by 35 cycles of 45 seconds at 9 4 T , 45 seconds at 5 4 T , 60 seconds at 72"C, and a final extension of 5 minutes at 72"C), and P2-microglobulin (4 minutes at 94°C followed by 30 cycles of 30 seconds at 5 7 T , 1 minute at 7 2 T , 30 seconds at 9 4 T , and a final extension of 10 minutes at 72°C). For CD26 and CD40L, experiments were also performed by increasing (40) or decreasing (30) amplification cycles to derive additional information on the relative amounts of specific mRNAs. The CD40L (sense, 5'-GCG GCA CAT GTC ATA AGT-3', region 406-423; antisense, 5'-GCC CGC AAG GTT TGG CGG AA-3', region 697-678) primer set was obtained from Stratagene (La Jolla, CA). CD26 (sense, 5'-ATT CCA AAC AAC ACA CAG T-3', region 453-472; antisense, 5'-CTT CAT AAA CCC AGT CAG T-3', region 625-606) and P2-microglobulin (sense, 5'-CTC GCG CTA CTC TCT CTT TCT-3', region 1-21; antisense, 5'-TCC ATT CTT CAG TAA GTC AAC T-3', region 162-141) primer sets were also used. Ten microliters of amplified cDNA was run in a 1.5% agarose gel. Negative control reactions were performed for each sample by performing PCR amplification omitting the mRNA reverse transcription step.
Clinical Features
Medical records of patients with T-cell lymphomaslleukemias enclosed in the present study were reviewed. Clinical data included age, sex, performance status, lactate dehydrogenase (LDH) levels, site of disease at presentation, treatment modalities, response, duration of response, and survival. The stage of disease at presentation was assigned according to the Ann Arbor staging system, except for mycosis fungoides patients, for whom the staging criteria proposed by Bunn and Lamberg3' were adopted. Patients received specific treatment modalities according to age and to institutional protocols for the various NHL subgroups. In particular, the LSA2-L2 protocol4' was adopted for patients with T-cell lymphoblastic lymphomas, whereas patients with T-ALL were treated according to the 02 88 GIMEMA study protocol!' Complete response (CR) was defined as the disappearance of all evaluable lesions lasting at least 1 month. Partial response (PR) was defined as more than 50% reduction in the sum of the products of the cross sectional diameters of all measurable lesions. Disease progression (Pro) was defined as any tumor reduction not qualifying for PR, as the increase in the size of measurable lesions, or as the appearance of new lesions. For T-ALL patients, CR was defined according to the standard criteria of Cancer and Leukemia Group B. Response duration was computed from the start of treatment to the date of documented disease recurrence or progression. Survival curves were defined according to the product-limit method!' Differences between subgroups were first assessed by means of the log-rank test4' and then by the Cox including all variables that were significantly associated with prognosis in the univariate analysis. Differences in LDH values in subgroups of patients were also evaluated using the Mann-Whitney U-Wilcoxon test." 
RESULTS
The well-characterized panel of 67 different T-cell NHL/ leukemias included cutaneous T-cell lymphomas (CTCL; 24 cases), T-cell lymphoblastic lymphomas (LBL; 15 cases), peripheral T-cell lymphomas (PTCL; 10 cases), CD30+ ALC lymphomas (8 cases), T-ALL (8 cases), and small lymphocytic T-cell neoplasm (2 cases). Immunologic analysis showed different tumor cell immunophenotypes (CD4+/ CDK; CD4+/CD8+; and CD4-/CD8-; Table 1 ).
Expression of CD26 and CD4OL in T-cell NHULeukemias
Immunoreactivity of anti-CD26 MoAb TA5.9 and anti-CD40L MoAb M90 in the total series of NHLAeukemias, based on the above described criteria (see Materials and Methods), is listed in Table 1. CD26. CD26 was expressed in 25 of 67 (37%) T-cell lymphomas/leukemias studied. The staining pattern on tissue sections was of moderate to strong intensity, both on the cell membranes and cytoplasms (Fig 1) . A paranuclear staining also was observed (Fig 2) . In positive cases, 80% to 100% of tumor cells were labeled. CD26 expression mainly clustered in the T-cell LBL/ALL group, in which 12 of 23 (52%) cases were positive (Fig l) , and in CD30+ ALC lymphomas, in which 5 of 8 (63%) cases showed staining for CD26 (Fig  2) . Among the other 8 CD26-expressing lymphomas, 5 cases were CTCL, 1 case PTCL, and 2 cases small lymphocytic ="--l T neoplasms. Different immunophenotypes (CD4+/CD8-, 12 cases; CD4-/CD8-, 9 cases; and CD4'/CD8', 4 cases; Table 1 ) were found among the CD26' lymphomas.
CD40L. Overall, 18 of the 67 (27%) T-cell lymphomas/ leukemias expressed immunodetectable CD40L (Table 1) . Membrane surface andor cytoplasmic immunoreactivity for CD40L was detected in most neoplastic cells in each case that was found to be positive (Figs 3 and 4) . T-cell lymphomas (16/18) were CD4+/CD8-neoplasms (Table l). The remaining 2 CD40L' T-cell lymphomas (l CTCL non-mycosis fungoides and 1 LBL) displayed the CD4-/ CD8-phenotype (Table 1) . Interestingly, CD26 and CD4OL coexpression was found only in 2 cases of the mycosis fungoides group and in 1 case of small lymphocytic lymphoma (T-cell chronic lymphocytic leukemia), whereas in all of the other 37 lymphoma cases the expression of the two antigens was mutually exclusive. In detail, CD26'/CD40L-and CD26-/CD40L' phenotypes were observed in 22 and 15 samples, respectively, whereas the remaining 27 lymphoma cases were negative for both antigens ( Table 1) . The overall lack of CD26 and CD40L coexpression in our series of lymphoma samples (64/67) was statistically significant (x: test, P S .OO1). The results of our phenotypic analysis also evidenced a preferential expression of CD4OL by cutaneous T-cell lymphomas and of CD26 by T-cell lymphoblastic malignancies ( Table 1 ). The differential distribution of these two molecules was statistically significant (CD40L CTCL v LBUT-ALL, x: = 12.23, P = .0005; CD26: CTCL v LBLR-ALL, x: = 5.00, P = .03).
Based on tissue or cell samples availability, the distribution of CD45 molecule isoforms among CD26' and CD40L' tumors was also investigated ( Table 2 ). All of the CD4OL-expressing T-cell tumors were CD45RO" (1 8/1 8). whereas about 50% of CD26' cases (1 3/23) expressed the CD45RO' phenotype. Accordingly, most of CD40L' cases (6/10) tested with the OPD4 MoAb, recognizing a restricted epitope of CD45R0, were also reactive with this antibody. In contrast, OPD4' tumor cells were found only in less than one-third ( 41 14) of the CD26' lymphomas tested. CD45RA determinants were distributed more frequently among CD26' (8/10) than among CD26-tumors (8/16). A similar pattern of CD45RA expression was also found in CD40L' (5/7) and CD40L-(1 1/19) lymphomas.
Expression of CD26 and CD4OL in Leukemidymphoma T-cell Lines
The mutual exclusion of CD26 and CD4OL evidenced on primary lymphoma T cells was confirmed by using a panel of 10 continuous cell lines derived from different human Tcell malignancies. As indicated by flow cytometry, immunocytochemistry, and RNA studies, 8 of 10 continuous cell lines of different T-cell phenotypes (CD4-/CD8-; CD4'/ CD8'; and CD4'/CD8-) were shown not to coexpress CD26 and CD4OL, even by adopting a highly sensitive RT-PCR For personal use only. on October 22, 2017. by guest www.bloodjournal.org From technique ( Table 3) . Simultaneous expression of CD26 and CD4OL was only found in H9 and Karpas 299; also, the relative amounts of the two antigens were inversely proportional in these cell types. In H9 cells, a significant expression of CD40L (mRNA and protein) was paralleled by a dim CD26 staining (25% of cells) and a low amount of CD26 RNA (ie, evidenced only after 40 cycles of amplification), whereas Karpas 299 cells strongly stained with anti-CD26 MoAbs (99% of cells) but displayed a very low level of CD40L mRNA (Table 3 ). The erythroleukemia cell line K562 was selected as an internal negative control for both CD26 and CD40L in immunostaining and RT-PCR experiments (Table 3 ). All cDNAs yielded the expected 162-bp amplified band when tested with primers specific for p2-microglobulin (data not shown). The expression pattern of CD26 and CD40L remained unmodified in most of the T-cell lines upon activation by TPA or TPA plus ionomycin for 2 to 48 hours, which conversely resulted in the upregulation of other surface structures, including CD25, CD38, CD54, and CD71 (data not shown).
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Expression of CD26 and CD4OL in Non-Neoplastic T-cell Expansion and During Activation of Normal T Cells
The patterns of expression of CD26 and CD40L in nonneoplastic expansions of activated T cells due to chronic and acute inflammatory conditions and during in vitro activation of normal T lymphocytes were analyzed by serial sections immunohistochemistry and flow cytometry. In the expanded paracortical area of all non-neoplastic (reactive) lymph nodes, which were predominantly populated by CD4' T lymphocytes, both CD4OL' and CD26' cells were detected (Fig   CARBONE ET AL   5A and B). Serial sections provided immunoarchitectural evidence of a similar immunostaining with both markers by the CD4' T-cell population. However, in residual follicles, some CD40L' lymphocytes were seen, whereas cells positive for CD26 were consistently absent (Fig 5A and B) .
Purified peripheral lymphocytes from subjects with nonneoplastic expansions of activated CD4' T cells, mostly related to acute or chronic inflammatory disorders (see Materials and Methods), were also analyzed for CD26 and CD40L expression. Activated CD4+/HLA-DR' T cells in these patients ranged from 70% to 85% of circulating T lymphocytes (data not shown). Results of dual-color flow cytometry showed that almost all CD40L' T cells (ranging from 35% to 60% of CD4' lymphocytes) coexpressed CD26 (Fig X ) .
A representative experiment illustrating the kinetic of CD26 and CD40L expression during in vitro activation of normal peripheral CD3' T lymphocytes and purified CD4' T cells by TPA and ionomycin is shown in Fig 6. An early peak of CD40L expression was observed in both total CD3' (25% to 28% of positive cells; Fig 6A) and purified CD4' (48% to 45% of positive cells; Fig 6B) T cells after 6 to 12 hours of activation, followed by a return to basal levels (<5% of positive cells) within 48 to 78 hours. In contrast, CD26 expression on activated CD3+ cells reached a maximum (71% of positive cells) at 78 hours (Fig 6A) . Purified CD4' cells displayed the highest basal levels of CD26 expression (>SO% of positive cells), which was further increased after activation with a maximum at 78 hours, when more than 90% of cells showed surface CD26 (Fig 6B) . Dual-color immunofluorescence experiments performed at the the peak of CD40L expression (12 hours) disclosed that, in both total CD3' cells (Fig 6A, inset) and purified CD4' lymphocytes ( Fig 6B, inset) , almost all CD40L' cells coexpressed CD26. Similarly, CD26' CD3' or CD4' cells were found to constitute the majority of CD40L expressing T lymphocytes at 6 and 24 hours after activation (data not shown).
Correlations of CD26 and CD4OL Expression With Clinical Features
The clinical characteristics of patients affected by T-cell LBL/ALL and by mycosis fungoides were separately analyzed according to CD26 and CD40L expression.
Within the T-cell LBL/ALL group (Table 4) , tumor cells expressed CD26 in 52% of patients. No significant relationships between CD26 expression and clinical features, such as sex, stage of disease at presentation, and response to therapy, were evidenced (Table 4 ). However, the median age of CD26' patients was higher (34.5 years; range, 8 to 80 years) as compared with CD26-subjects (median, 24 years; range, 8 to 43 years). In addition, no significant differences in mean LDH levels at diagnosis were evidenced between CD26-(773 t 387 IUL) and CD26' (633 -t 448 IUL) patients. Noticeably, the median survival of CD26 + patients was 6.0 months (range, 2 to 18 months), with only 1 patient still surviving. Eleven of 12 patients with CD26' tumors survived shortly after diagnosis and died of disease progression, despite the initial complete remission achieved with chemotherapy in 4 of these subjects (Table 4 ). In contrast, the median actuarial survival of patients with CD26-tumors was not yet reached at the time the present report was written (x: = 18.85; P S .OOOl), with all of these subjects being alive and in continuous complete remission. Such difference remained statistically significant also &er adjustment by age (x: = 13.48; P = .0002) and LDH levels (x: = 8.85; P = .003). The expression of CD26 in T-cell LBUALL therefore appeared to be associated with a worse prognosis in terms of survival, irrespective of age, LDH levels, and the initial good response obtained with chemotherapy.
Interestingly, a similar correlation between CD26 expression and a poor clinical outcome was also apparent in 2 patients affected by CD4+/CD26+ T-cell small lymphocytic neoplasm (Table 1) . Even though the natural history of this disease is not usually aggressive, both of these patients displayed a very short survival period (4 and 10 months, respectively) and died of disease progression despite chemotherapy (data not shown).
Among 21 patients affected by mycosis fungoides, tumor cells expressed a CD40L+/CD26-phenotype in 9 subjects. CD40L-/CD26+ (2 patients) and CD40L+/CD26' (2 patients) tumor cell phenotypes were also detected in this group of lymphomas ( Table 1) . No statistically significant correlations of both CD4OL and CD26 antigen expression with clinical features at presentation, including age and stage, response to therapy, or survival, were evidenced (data not shown). The other subgroups of patients (non-mycosis fungoides CTCL, PTCL, and CD30' ALC lymphoma) were too small to draw any correlation about CD26 or CD4OL expression and clinical features. In the present report, we have investigated the comparative expression of CD4OL and CD26 in a large series of wellcharacterized T-cell lymphomdeukemia samples of different immunophenotypes (CD4+/CD8-; CD4+/CD8+; and CD4-/CD8-). Expression of CD26 was mainly detected on immature T-cell malignancies such as LBL/T-ALL and CD30' ALC lymphomas, whereas CD40L+ lymphomas included a large fraction of cutaneous T-cell lymphomas. Even though the overall frequency of CD26 and CD40L+ samples was rather similar (37% v 27%), our phenotypic data indicated that tumor cells coexpressed both antigens in only 3 of 67 cases (P < .001). Similarly, by analyzing a panel of 10 1eukemiaAymphoma T-cell lines, CD26 and CD40L coexpression was found in only two cell types (H9 and Karpas 299), even when using a highly sensitive RT-PCR technique. Based on these results, it appeared overall that the expression of the two antigens was mutually exclusive in almost all T-cell lymphomasfleukemias analyzed.
The biologic basis accounting for the mutual exclusion of CD26 and CD40L expression in human T-NHL is currently unknown. Present and previous data indicate that CD26 and CD40L are differently regulated in non-neoplastic T cells. CD26 is constitutively expressed on a fraction (30% to 50%) of normal resting T l y m p h o~y t e s~~,~~ and is further increased on cellular activation, with a sustained peak at 48 to 78 h o~r s . " .~~ In contrast, CD40L is not expressed on resting peripheral T cells, but it is rapidly (6 to 12 hours) and transiently expressed after cellular activation, returning to baseline levels by 24 to 48 hours. Similarly, our detection of CD26 and CD40L on non-neoplastic T cells (lymph nodes and peripheral blood) from patients with chronic and acute inflammatory disorders may reflect that these lymphocytes are activated as the result of the inflammatory cytokine network triggered by the underlying disease. Based on these data it can be concluded that, although normal or non-neoplastic reactive T lymphocytes may coexpress CD26 and CD40L at a given phase of functional activation, as clearly shown by dual-color immunofluorescence, tumor T cells in vivo appear overall to lack this feature. A possibility is that CD26-/CD40L+ lymphomas may reflect the aberrant deletion of CD26 due to neoplastic transformation. Several Tcell-associated antigens are in fact characteristically lost in T-cell tumor^^^^'^^^ and the loss of CD26 has been associated with neoplastic transformation of different cell type^.*'.^^,^' Alternatively, the CD26-/CD40L+ phenotype may result from the dysregulated or aberrant expression of CD40L in some T-cell This is an intriguing hypothesis given that CD40L expression is subjected to a very tight regulation during physiologic processes of T-celVB-cell colstudies most T-cell tumors are identified by relying on the loss or aberrant expression of pan-T antigen^^.^'.''.^^ our data showing that CD26 and CD4OL are almost mutually exclusive in T-cell neoplasia provide an additional diagnostic finding in the majority of such neoplasms. However, further studies are needed to conclusively demonstrate this possibility.
We have investigated whether CD26' or CD40L' tumor T cells mirrored their putative normal counterparts as to the expression of CD45 isoforms associated with memory (CD45RO) and naive (CD45RA) T-cell functions.55 All of CD40L expressing lymphomas were of CD45RO phenotype, even though a fraction of CD40L+ tumors coexpressed the CD45RA isoform. These data are in agreement with the laboration.".".49.S0 Because in the absence of DNA clonality previous finding that CD40L expression on activated normal CD4' T cells is not restricted to a specific CD45 phenotype." Conversely, CD26+ T-cell lymphomas coexpressed the CD45RO antigen in about 50% of the cases, and the CD45RA isoform was found both in CD26+ and CD26-lymphomas. These findings are in apparent contrast with previous results indicating that CD26' T cells represent the memory pool5h." and that CD26 is physically associated with the CD45RO antigen." However, later studies have suggested that the expression of CD26 may not be restricted to cells bearing memory markers (CD45RO and CD29)" and evidenced CD26+/CD45RA+ subsets among normal T cells." Whether CD26+/CD45RO-and CD26+/CD45RA' T-cell lymphomas arise from these subsets or rather mirror antigen loss due to neoplastic transformation remains to be established.
No specific information is currently available about the clinical significance of CD40L and CD26 expression in human lymphomas, although the relevance of both these molecules for the diagnosis and treatment of some T-cell neoplasms has been recently underlined.11.17.2h
We did not observe any significant difference in clinical features and outcome among patients with CD4OL' or CD40L-cutaneous T-cell tumors. However, the heterogenity of treatments delivered to this group of patients and the smouldering behavior of the disease should be taken into account. Conversely, the expression of CD26 in T-cell LBL/ ALL patients was statistically associated with a more advanced age and a worse outcome in terms of survival, as compared with patients with CD26-tumors receiving similar chemotherapy regimens. Almost all of the patients with CD26+ tumors, including young adults, displayed a short CR duration and eventually succumbed to their disease, leading to a statistically significant difference in survival as compared with CD26-patients ( P 5 ,0001). Such a difference persisted after adjustement for age ( P = .0002) and LDH values at diagnosis ( P = ,003). However, the prognostic significance of CD26 expression in the present series of human T-cell lymphomas is a novel and intriguing finding that needs to be confirmed on a larger cohort of patients.
How the expression of CD26 may provide a growth advantage to malignant T cells remains to be fully established, but several lines of evidence clearly indicate that this molecule has a direct stimulatory function for T-cell prolifera-CD26 is able to transduce strong comitogenic signals in T ~e l l s '~.~"~'~~~.~~~~" that are mediated in part by the increased activity of the ~5 6 "~ k'na.ie 1y.5y.ho Moreover, T lymphocytes expressing CD26 display an enhanced production of cytokines capable of stimulating cell growth in an autocrine fashi0n,4"~' such as interleukin-2 (IL-2) and interferon-? (IFN-y) .58,6',hZ Accordingly, chemical inhibitors of CD26 are able to suppress T-cell proliferation and IL-2 production.h2,63 A further link between CD26 expression on malignant T lymphocytes and enhanced cellular proliferation and IL-2 production has also been provided by transfectant studies of mutagenized CD26 molecules lacking DPPIV activity. The results of the present study indicate overall that the constitutive expression of CD26 and CD40L in human Tcell lymphomas is mutually exclusive and that each of these molecules may reflect different biologic properties of neoplastic T cells.
